0000000001001763

AUTHOR

Pp Toth

showing 4 related works from this author

Step-by-step diagnosis and management of the nocebo/drucebo effect in statin-associated muscle symptoms patients: a position paper from the Internati…

2022

Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with statin therapy [most commonly statin-associated muscle symptoms (SAMS)] result in the discontinuation of therapy and consequently increase the risk of adverse cardiovascular outcomes. However, complete statin intolerance occurs in only a small minority of treated patients (estimated prevalence of only 3-5%). Many perceived AEs are misattributed (e.g. physical musculoskeletal injury and inflammatory myopathies), and subjective symptoms occur as a result of the fact that patients expect them to do so when taking medicines (the nocebo/drucebo effect)-what might be truth even for over 50% of all patients wit…

KardiologiDrucebo effect Nocebo effect SAMS Statin intoleranceMusclesSAMSNocebo effectLipidsQPRSStatin intolerance.Muscular DiseasesStatin intolerancePhysiology (medical)Drucebo effectHumansOrthopedics and Sports MedicineCardiac and Cardiovascular SystemsHydroxymethylglutaryl-CoA Reductase Inhibitorsdrucebo effect ; nocebo effect ; SAMS ; statin intoleranceJournal of Cachexia Sarcopenia and Muscle
researchProduct

A meta-analysis of the role of statins on renal outcomes in patients with chronic kidney disease. Is the duration of therapy important?

2013

article i nfo Introduction: The efficacy of statin treatment in chronic kidney disease (CKD) patients remains controversial. Therefore, we performed a meta-analysis to investigate whether statins modulate renal function in patients with CKD. Methods: Data from Scopus, PubMed, Web of Science, and the Cochrane Central Register of randomized controlled trials for years 1966-December 2012 were searched for appropriate studies. Results: Twenty trials with 6452 CKD subjects randomized to receive either statin or placebo were included. Statin therapy significantly influenced high sensitivity C-reactive protein levels in patients on or off dialysis (−0.28 mg/dl, 95%CI: −0.93 to −0.37; p b 0.05 and …

medicine.medical_specialtyStatinmedicine.drug_classmedicine.medical_treatmentRenal functionPlaceboGastroenterologyBlood Urea Nitrogenlaw.inventionchemistry.chemical_compoundRandomized controlled trialRenal DialysislawInternal medicinemedicineHumansRenal Insufficiency ChronicIntensive care medicinechronic kidney disease creatinine dialysis meta-analysis renal outcomes statin urinary proteinDialysisRandomized Controlled Trials as TopicCreatininebusiness.industrymedicine.diseaseTreatment OutcomechemistryCardiovascular DiseasesCreatinineMeta-analysisHydroxymethylglutaryl-CoA Reductase InhibitorsCardiology and Cardiovascular MedicinebusinessGlomerular Filtration RateKidney disease
researchProduct

Analysis of the impact of sex and age on the variation in the prevalence of antinuclear autoantibodies in Polish population: a nationwide observation…

2022

AbstractThe detection of antinuclear autoantibody (ANA) is dependent on many factors and varies between the populations. The aim of the study was first to assess the prevalence of ANA in the Polish adult population depending on age, sex and the cutoff threshold used for the results obtained. Second, we estimated the occurrence of individual types of ANA-staining patterns. We tested 1731 patient samples using commercially available IIFA using two cutoff thresholds of 1:100 and 1:160. We found ANA in 260 participants (15.0%), but the percentage of positive results strongly depended on the cutoff level. For a cutoff threshold 1:100, the positive population was 19.5% and for the 1:160 cutoff th…

musculoskeletal diseasesAdultMaleRMAnti-nuclear antibodyCross-sectional studyIndirect immunofluorescence assayImmunologyPopulationAdult populationPolish populationObservational ResearchAutoimmune DiseasesAgeSex FactorsRheumatologyCutof thresholdPrevalenceImmunology and AllergyCutoffMedicineHumanseducationskin and connective tissue diseasesQH426education.field_of_studybusiness.industryAutoantibodyAge FactorsMiddle AgedQRCutoff thresholdstomatognathic diseasesAntinuclear antibodiesCross-Sectional StudiesIndirect immunofuorescence assayAntibodies AntinuclearQR180Observational studySexFemalePolandbusinessDemographyRheumatology International
researchProduct

Emerging Therapies For Raising Hdl-C And Augmenting Hdl Particle Functionality

2013

High-density lipoprotein particles are highly complex polymolecular aggregates capable of performing a remarkable range of atheroprotective functions. Considerable research is being performed throughout the world to develop novel pharmacologic approaches to: (1) promote apoprotein A-I and HDL particle biosynthesis; (2) augment capacity for reverse cholesterol transport so as to reduce risk for the development and progression of atherosclerotic disease; and (3) modulate the functionality of HDL particles in order to increase their capacity to antagonize oxidation, inflammation, thrombosis, endothelial dysfunction, insulin resistance, and other processes that participate in arterial wall inju…

apoA-I mimetic coronary artery disease delipidation endothelial lipase inhibitor farnesoid X receptor high-density lipoproteins liver X receptor reverse cholesterol transport RVX-208
researchProduct